Quantitative dysmorphology assessment in Fabry disease

Genetics in Medicine

Volumn 8, Issue 2, 2006, Pages 96-101

  Ries, Markus ^a   Moore, David F ^b   Robinson, Chevalia J ^a   Tifft, Cynthia J ^c   Rosenbaum, Kenneth N ^c   Brady, Roscoe O ^a   Schiffmann, Raphael ^a   Krasnewich, Donna ^d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Diagnosis; Dysmorphology; Enzyme therapy; Fabry Disease *genetics; X linked

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AWARENESS; CLINODACTYLY; ENZYME REPLACEMENT; EVALUATION; EYEBROW; FABRY DISEASE; HEMIZYGOSITY; HUMAN; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; MORPHOMETRICS; NEUROPATHIC PAIN; NOSE; NOSE CARTILAGE; PATIENT SELECTION; PERIORBITAL EDEMA; QUANTITATIVE ANALYSIS; SCHOOL CHILD; STANDARDIZATION; STATISTICAL ANALYSIS; TERATOLOGY; CHILD; CLUSTER ANALYSIS; COHORT ANALYSIS; CONGENITAL MALFORMATION; FACE; FINGER; GENETICS; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; THORAX;

DUDLEYA EDULIS;

ADOLESCENT; ADULT; CHILD; CLUSTER ANALYSIS; COHORT STUDIES; FABRY DISEASE; FACE; FINGERS; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; THORAX;

EID: 33645411928     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000200950.25118.dd     Document Type: Article

References (45)

1. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorragica Hebrae). Arch Dermatol Syphilis 1898;43:187-200.
2. Andersen W. A case of angiokeratoma. Br J Dermatol 1898;18:113-117.
3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167.
4. Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet 1983;20:309-312.
5. O'Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, Anholt L, Freeman H, Thomson AB. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. Gastroenterology 1982;82:957-962.
6. Klug H, Zabel R, Evers U. [Fabry disease: clinical, biochemical and electron microscopical studies (author's transl)]. Dermatol Monatsschr 1979;165:46-54.
7. Tsukada N, Hanu N, Oguchi K, Yanagisawa N, Tsukagoshi H, Hattori H. [Fabry's disease with malocclusion and acromegalic-appearance: clinical and electromicroscopic studies (author's transl)]. No To Shinkei 1980;32:311-319.
8. Le Charpentier Y, Crouzet J, Le Charpentier M, Lessana-Leibowitch M, Di Crescenzo MC, Bennett B, Abelanet R. [Fabry's disease without cutaneous angiokeratoma: diagnosis by electron microscope study of skin biopsy (author's transl)]. Semin Hop 1981;57:78-82.
9. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002;13:S134-S138.
10. Sessa A, Toson A, Nebuloni M, Pallotti F, Giordano F, Battini G, Maglio A, Meroni M, Calconi G, Bertolone G, Gatti P. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 2002;15:109-112.
11. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R. Pediatric Fabry disease. Pediatrics 2005;115:e344-355.
12. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, Gal A, Beck M. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003;162:767-772.
13. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002;13:S147-149.
14. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-138.
15. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, Schiffmann R. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
16. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749.
17. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
18. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-710.
19. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
20. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-844.
21. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760.
22. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307.
23. Nayler JR. Clinical photography: a guide for the clinician. J Postgrad Med 2003;49:256-262.
24. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994:248-292.
25. Conger AJ. Integration and generalisation of Kappas for multiple raters. Psychological Bulletin 1980;88:322-328.
26. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurements 1960;20:37-46.
27. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991:397-439.
28. Cohen MM, Jr. Syndromology: an updated conceptual overview. VI. Molecular and biochemical aspects of dysmorphology. Int J Oral Maxillofac Surg 1989;18:339-346.
29. Landing BH, Silverman FN, Craig JM, Jacoby MD, Lahey ME, Chadwick DL. Familial Neurovisceral Lipidosis. An Analysis of Eight Cases of a Syndrome Previously Reported as "Hurler-Variant," "Pseudo-Hurler," and "Tay-Sachs Disease with Visceral Involvement". Am J Dis Child 1964;108:503-522.
30. Sandhoff K, Andreae U, Jatzkewitz H. Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci 1968;7:283-288.
31. Krivit W, Desnick RJ, Lee J, Moller J, Wright F, Sweeley CC, Snyder PD, Jr., Sharp HL. Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain. Sandhoff's disease (variant of Tay-Sachs disease). Am J Med 1972;52:763-770.
32. Maroteaux P, Lamy M. La pycnodysostose. Presse Med 1962;70:999-1002.
33. Palo J, Santavuori P, Haltia M. Recent findings on some "new" neurometabolic diseases. Riv Patol Nerv Ment 1976;97:191-198.
34. Beck M, Barone R, Hoffmann R, Kratzer W, Rakowsky T, Nigro F, Fiumara A. Inter-and intrafamilial variability in mucolipidosis II (I-cell disease). Clin Genet 1995;47:191-199.
35. Ockerman PA. A generalized storage disorder resembling Hurler's syndrome. Lancet 1967;II:239-241.
36. Cooper A, Sardharwalla IB, Roberts MM. Human beta-mannosidase deficiency. N Engl J Med 1986;315:1231.
37. Wenger DA, Sujansky E, Fennessey PV, Thompson JN. Human beta-mannosidase deficiency. N Engl J Med 1986;315:12011205.
38. Van Hoof F, Hers HG. Mucopolysaccharidosis by absence of alpha-fucosidase. Lancet 1968;1:1198.
39. Spranger J, Gehler J, Cantz M. Mucolipidosis I-a sialidosis. Am J Med Genet 1977;1:21-29.
40. Goldberg MF, Cotlier E, Fichenscher LG, Kenyon K, Enat R, Borowsky SA. Macular cherry-red spot, corneal clouding, and -galactosidase deficiency. Clinical, biochemical, and electron microscopic study of a new autosomal recessive storage disease. Arch Intern Med 1971;128:387-398.
41. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976;54:818-825.
42. Horiuchi H, Saito N, Kobayashi S, Ota H, Taketomi T, Takaoka K. Avascular necrosis of the femoral head in a patient with Fabry's disease: identification of ceramide trihexoside in the bone by delayed-extraction matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum 2002;46:1922-1925.
43. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979;97:671-676.
44. Gemignani F, Pietrini V, Tagliavini F, Lechi A, Neri TM, Asinari A, Savi M. Fabry's disease with familial lymphedema of the lower limbs. Case report and family study. Eur Neurol 1979;18:84-90.
45. Baccaglini L, Schiffmann R, Brennan MT, Lancaster HE, Jr., Kulkarni AB, Brahim JS. Oral and craniofacial findings in Fabry's disease: a report of 13 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:415-419.